ATC Group: L01FY01 Pertuzumab and trastuzumab

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L01FY01 in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L01 Antineoplastic agents
3 L01F Monoclonal antibodies and antibody drug conjugates
4 L01FY Combinations of monoclonal antibodies and antibody drug conjugates
5 L01FY01

Active ingredients in L01FY01

Active Ingredient

Pertuzumab and trastuzumab are recombinant humanised IgG1 monoclonal antibodies which target the human epidermal growth factor receptor 2 (HER2). Both substances bind to distinct HER2 subdomains without competing and have complementary mechanisms for disrupting HER2 signalling. Additionally, both substances mediate antibody-dependent cell-mediated cytotoxicity (ADCC).

Related product monographs

Document Type Information Source  
 PHESGO Solution for injection MPI, EU: SmPC European Medicines Agency (EU)

United States medicines

Medicines classified under this ATC code globally

Austria (AT)

Canada (CA)

Croatia (HR)

Ecuador (EC)

Estonia (EE)

Finland (FI)

France (FR)

Hong Kong (HK)

Ireland (IE)

Israel (IL)

Italy (IT)

Lithuania (LT)

Netherlands (NL)

Nigeria (NG)

Poland (PL)

Romania (RO)

South Africa (ZA)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.